TxCell is working on new ways of delivering its Crohn's disease therapy Ovasave that will replace the somewhat unusual method it is using in clinical trials.
CSL Behring has opted to extend the half-life of its haemophilia B treatment Idelvion using a technology developed by Novozymes A/S subsidiary Albumedix.
An influenza vaccine produced in tobacco plants could make a big impact in the market if it reaches the market in the US in time for the 2018-19 flu season, says a market analyst.
Researchers studying chemical reactions in urine have created an adhesive gel for drug delivery applications that they say is cheaper and easier to make than hydrogel-based carriers.
Drugs currently being used to treat psychosis or depression may be able to treat emerging viruses, according to new research led by the University of Leeds.
Researchers at Ohio State University are hiding cancer drugs inside a “molecular Trojan horse” in order to successfully infiltrate drug-resistant cells.
Grünenthal has selected Patheon as its preferred development partner for its anti-abuse formulation platform INTAC, based on Hot Melt Extrusion (HME) technology.
Sanofi is poised to terminate its Auvi-Q marketing deal says PDL Biopharma, citing manufacturing issues last year which led to a complete recall of the epinephrine injection product.
Japanese researchers have developed a peptide vaccine with the potential to protect the brain when administered prior to a stroke, according to a study presented at the American Stroke Association’s International Stroke Conference.
Teva has aggressively defended its market share for its blockbuster Copaxone says Momenta, six months after marketing partner Sandoz launched the first generic version in the US.
Capsugel has come on leaps-and-bounds since it was spun-out from Pfizer, the firm says as it inks a deal with Pulmatrix to develop inhaled therapeutics.
Qualicaps has swapped a manufacturing technology customer for dominance of Brazil's fast growing pharmaceutical capsule market through a recent acquisition.
Up to 90% of new chemical entities having properties that make them a challenge to successfully formulate, says Juniper Pharmaceuticals which has won a reformulation and manufacturing contract from PharmAust.
MannKind has spoken about Receptor Life Science, a newly-formed company which last month licensed the Technosphere inhaled delivery platform from the struggling firm.
Novartis subsidiary Sandoz will commercialise small and large molecule injectables using French delivery tech firm MedinCell’s subcutaneous controlled release platform.
Recipharm has raised SEK276m ($32m) to part finance the acquisition of a majority stake in Indian CMO Nitin Life Sciences that it announced in October.
Catalent will pursue strategic acquisitions and licensing in 2016, said VP Marketing & Strategy Elliott Berger, noting growth areas include complex delivery technologies and specialised logistics.
A Zika vaccine is a long way off according to a UK academic who suggested vaccines for related viruses could be used as delivery vectors to accelerate development.
Mucosis has been awarded a Wellcome Trust grant of €3.7m ($4m) to help develop a Respiratory Syncytial Virus (RSV) vaccine using its intranasal delivery platform.
Fresenius Kabi has moved into the prefilled syringe space by acquiring Becton, Dickinson and Company’s injectables business and US manufacturing plant.
Despite Sanofi’s “conflicted” management and subsequent abandonment of Afrezza, the market opportunity for inhaled insulin is still huge, according to Dance Biopharm's CEO.
Sanofi has abandoned Afrezza less than a year after its launch, but the future of the inhaled insulin product is secure according to developer MannKind.
Having a proactive approach to delivery technologies will give pharma firms a competitive edge against biosimilars and biobetters, according to device maker Bespak.
MIT engineers have designed a new hydrogel material that can incorporate temperature sensors, LED lights, and other electronics – in addition to drug-delivering reservoirs.
